Authors
Loading...
Randomized trial demonstrates eradication of neutralizing antibodies in a nonhuman primate model, suggesting B cell-targeting therapies may enhance gene transfer safety.
Mingozzi et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: